Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Sanofi SNY reported fourth-quarter 2024 adjusted ... In Others, Toujeo recorded sales of €290 million, up 6.5% year over year. Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s ...

The Sanofi Global Health Unit plays an important ... First, the impact of price cuts of Lantus in the U.S. in H1 for €1.1 billion. Second, the entire elimination of all factoring of receivables ...

He said that when Sanofi's senior decision-makers convene ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros ...

Paul Hudson, CEO of Sanofi, said the pharmaceutical company ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros ...